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1. Introduction 
Although around 80% of men aged 80 years and older and 15% to 30% of men aged 50 years 
and older have microscopic undiagnosed prostate cancer found at autopsy, only 3% men die 
because of prostate cancer.1 Increasing prostate-specific antigen (PSA) screening at younger 
ages has increased overdiagnosis2 and overtreatment3 of localized prostate cancer (LPC). More 
than 90% of US patients currently diagnosed with prostate cancer have LPC and 
approximately 94% of patients with LPC choose treatment.4 Based on data from leading 
studies, a model had recently projected only a 0% to 2% 15-year mortality from low-grade 
(Gleason score <7) screen-detected LPC in men aged 55 to 74 years if they chose observation 
instead oftreatment.5 By consensus, urologists and radiation oncologists recommend treatment 
for LPC if a patient has a further 10-year life expectancy 6 (the10-year rule7) regardless of 
cancer grade, even though no randomized trials have shown that treatment can improve 
survival in patients in whom the cancer was screen-detected. National guidelines by the 
American Cancer Society and the National Comprehensive Cancer Network (NCCN) also 
recommend treatment for most patients.8 However, in the review by Zeliadt et al,9 different 
studies had found that patients rate the sexual, urinary, and bowel side effects of treatment to 
be just as important as the potential benefit in survival; that if risks and benefits of treatment 
were explained with-out bias, 75% of patients chose a lower radiation dose despite a lower 
predicted survival; that 90% of physicians but fewer than 20% of patients ranked the effect of 
treatment on survival as one of their top 4 concerns; and that patients who chose treatment 
believed that treatment was guaranteed to improve survival. At a median of 6 years after 
treatment, health-related quality of life (HRQOL) of treated patients was worse than that of 
controlpatients.10 Many patients regretted that they chosetreatment.11 
To our knowledge, no studies of patient-physician communication have examined patients’ 
anticipated survival benefit of treatment. Without data from randomized trials in screen-
detected patients, it is difficult to counsel patients regarding their survival with and without 
treatment. Even with the use of multi-factorial models, accuracy of predicted survival is 75% 
or lower.12 Physicians are also poor at estimating baseline co-morbidity adjusted life 
expectancy (CALE), which is critical in making an informed decision.13 Thus, patients may 
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accept a treatment recommendation not knowing what their baseline CALE is, how much 
the newly diagnosed cancer could reduce it, or how effectively treatment could minimize 
that reduction. Current over-treatment of LPC might be because patients do not understand 
the pros and cons of treatment.  
In this study we surveyed newly diagnosed patients about their anticipation of survival with 
and without treatment. By estimating their baseline CALE without considering the newly 
diagnosed cancer, we calculated their perceived decrease in longevity with observation 
(PDLO), and their perceived increase in longevity with treatment (PILT) for the cancer. 
2. Methods 
We surveyed patients who had been newly diagnosed with LPC (stages T1a to T2c) in the 
preceding 6 months, had met with their urologist after the diagnosis, were scheduled to 
receive treatment or observation, and had not yet been treated with surgery or radiation. 
Patients with dementia, or those who could not read, write, or understand English, were 
excluded. All patients were recruited from a large, private urology practice in Norfolk, 
Virginia. Staff at this practice systematically contacted patients newly diagnosed with LPC 
between March 2005 and November 2007 regarding their interest in participation in a self-
administered mailed survey. Two concomitant pretreatment self-administered surveys were 
used. The first survey asked patients about expectations of survival with and without 
treatment, co-morbid diseases, mood, social support, satisfaction with life, health, and 
education by physicians about treatment options. A list of health-related words in a closed 
envelope was mailed with the survey. Patients were requested to open the envelope and 
read these words on the telephone to a research assistant. This was done to estimate patient 
health literacy by using a brief version of the Rapid Estimation of Health Literacy in 
Medicine scale.14 Patients were given a $10 stipend for completing this survey. A second 
pretreatment survey was a part of a longitudinal follow-up by urologists to evaluate generic 
HRQOL, prostate cancer related symptoms, and fear of cancer recurrence. The study 
methods were reviewed and approved by an Institutional Review Board. 
3. Measures 
The Charlson Comorbidity Index (CCI) is a validated measure of co-morbidity. We used a 
patient self-reported CCI scale that asked about the presence and severity of 12 chronic 
conditions; the Prostate Cancer Outcomes Study used this CCI version.15 Score categories 
are 0, 1, 2, and 3 or more diseases.  
The NCCN practice guidelines had recommended, for the first time in 2007,8 that the health 
adjusted life expectancy of LPC patients can be estimated by weighting age-based life 
expectancy by 1.5 for patients in the highest health quartile, using no weighting for patients 
in the middle 2 health quartiles, and weighting by 0.5 for patients in the lowest health 
quartile. We used co-morbidity scores as surrogate markers of health status because co-
morbidity is the main determinant of life expectancy in older patients, 16 and the most 
important prognostic factor for patients with LPC who are <75 years old is the co-morbidity 
score. 17 We categorized patients into health quartiles by using their CCI score (0 disease 
score = highest health quartile; 1 or 2 disease score = middle 2 health quartiles; 3 or higher 
disease score = lowest health quartile). Our basis of equating a 1 or 2 disease score with the 
middle 2 health quartiles was that almost half (49%) of the 3173 patients newly diagnosed 
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with LPC in a Prostate Cancer Outcomes Study15 had a disease score of 1 or 2, and almost 
half (55.5%) of our patients had a disease score of 1 or 2. Both studies used the same version 
and scoring of the CCI. Patients were placed in 4 CALE categories: <5 years, 5 to 10 years, 10 
to 20 years, and 20 years. These 4 categories were scored, respectively, from 1 to 4.  
Patients were asked the following 2 questions: “How long do you expect you will live without 
any treatment for prostate cancer?” (Q1) and “How long do you expect you will live after 
treatment for prostate cancer?” (Q2). The possible responses to both questions were grouped 
into 4 categories (similar to the CALE categories): <5 years, 5 to 10 years, 10 to 20 years, and 
>20 years. These 4 categories were also scored from 1 to 4, respectively. Based on Q1, Q2, and 
CALE scores, we calculated the patient’s PDLO (which is CALE category score minus Q1 
category score) and the patient’s PILT (which is Q2 category score minus Q1 category score). A 
PDLO of 10 or more years is at least a 2-category difference between the CALE category and 
the Q1 category; this is only possible if the CALE was >20 years and the Q1 response was 5 to 
10 years or if the CALE was 10 to 20 years and the Q1 response was <5 years. Similarly, a PILT 
of 10 or more years indicates that the response to Q2 was 10 years or more than the response to 
Q1. We conducted ordinal logistic regression analyses to identify the main socio-demographic, 
health, and cancer characteristics that could predict PDLO and PILT of 10 or more years.  
The following validated self-administered scales were used. (1) The Short-Form 36 (SF-36, 
version 2) measures generic HRQOL; we calculated physical component summary and 
mental component summary scores from SF-36 data.18 (2) The Prostate Cancer Index 
measures urinary, sexual, and bowel symptoms and how much they bother the patient.19 (3) 
The Duke Activity Status Index20 measures functional capacity in metabolic equivalents; this 
scale asks patients whether they could perform 12 activities which have different levels of 
exertion. (4) The Hospital Anxiety and Depression Scale measures the presence and severity 
of anxiety and depression.21 (5) The Fear of Cancer Recurrence Scale measures the fear of 
possible cancer recurrence.22 (6) The Medical Outcomes Study Social Support Survey 
measures social support in an overall score that includes multidimensional sub-scores. 23 (7) 
The Delighted-Terrible Seven Faces Scale24 was used to measure patient satisfaction with 
life, health, and with education given by physicians about treatment options for LPC. (8) 
The Rapid Estimation of Health Literacy in Medicine scale, discussed earlier, measures 
health literacy; this was the only scale administered by telephone.14 
4. Statistical analyses 
Frequencies and relative frequencies were used to describe categorical variables. 
Continuous variables were described using the mean, median, and SD. Chi-square tests, 
Fisher’s exact test, and independent sample t tests were used to examine bivariate 
associations. Unadjusted and adjusted odds ratios (ORs) and their 95% CIs were estimated 
using ordinal logistic regression analysis. Socio-demographic and health factors that were 
found to be associated with PDLO and PILT in the bivariate analysis at an alpha level of 0.20 
were kept in the multivariate models. All analyses were performed using SAS software 
(version 9.1, SAS Institute, Inc., Cary, NC). 
5. Results 
Surveys were mailed to 430 patients newly diagnosed with LPC, but 69 patients had already 
started treatment by the time the patients received the surveys, 3 patients never received the 
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surveys, and 2 patients were found to be ineligible to participate because their cancer was not 
localized to the prostate. Of the 356 remaining patients, 104 patients did not return the survey 
because they were “not interested” in participating and 68 patients who did not return the 
surveys did not give a reason for not participating or could not be contacted. One hundred 
eighty-four of 356 patients (survey response rate of 52%) completed and returned the first 
pretreatment survey; 23 of these 184 patients (12.5%) patients chose observation. Table 1 shows 
a demographic comparison of patients who chose treatment or observation. Mean patient age 
was 61.5 years, and most patients reported college education and a family income of >$50,000.  
 
Overall  Treatment Observation 
Characteristic  (n [%]) (n [%]) (n [%]) P‡  
Age (years)  n = 184 n = 161 n = 23  
<60  71 (38.6) 68 (42.2) 3 (13.0)  
60–70  91 (49.5) 81 (50.3) 10 (43.5)  
>70  22 (11.9) 12 (7.5) 10 (43.5) <.0001  
Mean +/- SD  61.5 +/- 7.9 60.6 +/- 7.6 68.2 +/- 5.9 <.0001  
Race  n = 184 n = 161 n = 23  
African American  26 (14.1) 26 (16.2) 0 (0.0)  
White  158 (85.9) 135 (83.9) 23 (100) .05§  
Education  n = 180 n = 157 n = 23  
<High school  7 (3.9) 7 (4.5) 0 (0.0)  
High school  65 (36.1) 56 (35.7) 9 (39.1)  
College  108 (60.0) 94 (59.9) 14 (60.9) .58  
Health literacy  n = 173 n = 150 n = 23  
Below 6th grade  1 (0.6) 1 (0.7) 0 (0.0)  
6th-9th grade  16 (9.3) 15 (10.0) 1 (4.4)  
>9th grade  156 (90.2) 134 (89.3) 22 (95.7) .63  
Family income  n = 179 n = 156 n = 23  
Low (>$50,000)  57 (31.8) 50 (32.0) 7 (30.4)  
High (=>$50,000)  122 (68.2) 106 (67.9) 16 (69.6) .88  
*Treatment patients had either surgery or radiotherapy. 
†Observation patients had neither surgery nor radiotherapy. 
‡Unless otherwise specified, statistical significance is for chi-square test (categorical variables) or 
independent samples t test (continuous variables). 
§Fischer’s exact test. 
Table 1. Comparison of Socio-demographic Characteristics of Patients with Localized 
Prostate Cancer who Chose Treatment* and Observation†  
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Table 2 shows a comparison of patients who chose treatment or observation by cancer grade, 
PSA, life expectancy by age, and co-morbidity scores. Mean Gleason grade was 6.6. Table 2 
also includes a comparison of these patient groups by SF-36 scores (Physical Component and 
Mental Component Scores), as well as the urinary, sexual, and bowel function scores of the 144 
of 184 patients who had also returned the second pretreatment survey. Table 3 shows a 
comparison of patients who chose treatment or observation by CALE, anxiety and depression, 
function capacity, social support, and satisfaction. Mean CALE was 22.9 years. Table 4 shows 
the baseline CALE for the 184 patients and the responses of 170 of the 184 patients who had 
answered questions about their perceived life expectancy without treatment (Q1) and with 
treatment (Q2) of the cancer. Without treatment, perceived life expectancy was <5 years in 
15.2%, 5 to 10 years in 48.8%, 11 to 19 years in 33.5% and 20 or more years in 2.4% of the 
patients. With treatment, it was <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, 
and 20 or more years in 62.9% of the patients. By contrast, baseline CALE was <5 years in 0.5%, 
5 to 10 years in 2.2%, 11 to 19 years in 36.4%, and 20 or more years in 60.9%. A total of 170 
patients had data on CALE, Q1, and Q2. As compared with CALE, 65 (38.2%) of these 170 
patients expected their survival to decrease by 10 or more years without treatment. As 
compared with their perceived survival without treatment, 81 (47.6%) of 170 patients expected 
their survival to increase by 10 or more years with treatment. Of the 108 patients with a 
baseline CALE of >20 years, only 2 (1.9%) expected to live beyond 20 years without treatment 
whereas 84 (77.8%) expected to live beyond 20 years with treatment (data not shown). Neither 
of these perceptions was significantly related to whether the patients chose treatment or 
observation. However, to a statistically insignificant extent, patients who chose treatment were 
more likely than observation patients to expect a 10 or more years reduction in survival 
without treatment (50% vs. 33.3%, _2 test; P = .26) and a 10 or more year increase in survival 
with treatment (39.9% vs. 16.7%, Fisher’s exact test; P =.13). 
 
Overall  Treatment  Observation  
Factors  (n [%])  (n [%])  (n [%])  P*  
Gleason Grade  n = 184  n = 161  N = 23   
2–4  0 (0.0)  0 (0.0)  0 (0.0)   
5–6  103 (55.9)  84 (52.1)  19 (82.6)   
7  62 (33.7)  60 (37.3)  2 (8.7)   
8–10  19 (10.3)  17 (10.6)  2 (8.7)  0.02  
Mean +/- SD  6.6 +/- 0.7  6.6 +/- 0.7  6.2 +/- 0.7  0.02  
Prostate-specific antigen  n = 183  n = 161  n = 23   
=<10  159 (86.9)  139 (86.3)  21 (91.3)   
>10  24 (13.1)  22 (13.7)  2 (8.7)  0.74  
Mean +/- SD  6.7 +/- 5.3  6.8 +/- 5.5  5.6 +/- 3.4  0.14  
Life expectancy by age 
(years)  
n = 183  n = 160  N = 23   
<10  4 (2.2)  2 (1.3)  2 (8.7)   
10–20  104 (56.8)  86 (53.8)  18 (78.3)   
>=20  75 (40.9)  72 (45.0)  3 (13.0)  0.002*  
Comorbidity score  n = 184  n = 161  N = 23   
www.intechopen.com
 
Topics in Cancer Survivorship 
 
272 
0  74 (40.2)  66 (40.9)  8 (34.8)   
1  75 (40.8)  67 (41.6)  8 (34.8)   
2  27 (14.7)  23 (14.3)  4 (17.4)   
>=3  8 (4.4)  5 (3.1)  3 (13.0)  0.16  
Mean +/- SD  0.9 +/- 1.0  0.83 +/- 0.96  1.26 +/- 1.5  0.18  
Short Form-36 subscales      
Physical component 
summary  
n = 142  n = 134  n = 8   
Mean +/- SD  54.5 +/- 7.6  54.5 +/- 7.2  52.6 +/- 12.3  0.66  
Mental component 
summary  
n = 142  n = 134  n = 8   
Mean+/- SD  44.1 +/-6.8  43.9 +/- 6.9  46.4 +/- 4.5  0.29  
Prostate cancer index      
Urinary  n = 141  n = 132  n = 9   
Mean +/- SD  90.2 +/- 16.9  90.1 +/- 17.4  91.3 +/- 9.3  0.83  
Bowel  n = 142  n = 133  n = 9   
Mean +/- SD  88.8 +/- 12.5  88.5 +/- 12.8  92.9 +/- 4.5  0.03  
Sexual  n = 137  n = 128  n = 9   
Mean +/- SD  57.7 +/- 29.9  57.8 +/-30.4  55.4 +/- 23.8  0.82  
Urinary Bother  n = 144  n = 135  n = 9   
Mean +/- SD  86.1 +/- 23.0  85.9 +/- 23.4  88.9 +/- 18.2  0.71  
Bowel Bother  n = 144  n = 135  n = 9   
Mean +/- SD  92.5 +/- 17.5  92.0 +/- 17.9  100 +/- 0.0  0.0001  
Sexual Bother  n = 142  n = 133  n = 9   
Mean +/- SD  65.8 +/- 36.8  65.4 +/- 36.8  72.2 +/- 38.4  0.59  
Fear of cancer recurrence  n = 141  n = 133  n = 8   
Mean +/- SD  10.7 +/- 3.8  10.7 +/- 3.7  10.9 +/- 4.5  0.92  
Table 2. Comparison of Patients who Chose Treatment and Observation by Prostate Cancer-
Related and Health Factors  
 
Overall  Treatment  Observation  
Characteristic  (n [%] (n [%]* **  (n [%]† ***  P‡ *  
Comorbidity-adjusted life 
expectancy 
    
All ages 184 (100)  161 (100)  23 (100)   
<5 years 1 (0.5)  0 (0)  1 (4.3)   
5–10 years 4 (2.2)  2 (1.2)  2 (8.7)   
11–19 years 67 (36.4)  52 (32.3)  15 (65.2)   
>=20 years 112 (60.9)  107 (66.5)  5 (21.7)  <.0001  
Mean +/- SD 22.9 +/- 7.6  23.9 +/- 7.3  < .0001  
Anxiety score  n = 183  n = 160  n = 23   
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None/normal (0–7) 145 (79.2)  123 (76.9)  22 (95.7)   
Mild anxiety (8–10) 23 (12.6)  23 (14.4)  0 (0.0)   
Moderate anxiety (11–14) 12 (6.6)  11 (6.9)  1 (4.4)   
Clinical (15–21) 3 (1.6)  3 (1.9)  0 (0.0)  .18  
Mean +/- SD 5.1 +/- 3.5  5.4 +/- 3.5  2.8 +/- 2.9  .0008  
Depression score  n = 178  n = 156  n = 22   
None/normal (0–7) 172 (96.6)  150 (96.2)  22 (100)   
Mild depression (8–10) 4 (2.3)  4 (2.6)  0 (0.0)   
Moderate (11–14) 1 (0.6)  1 (0.6)  0 (0.0)   
Clinical (15–21) 1 (0.6)  1 (0.6)  0 (0.0)  .83  
Mean +/- SD 1.7 +/- 2.3  1.7 +/- 2.4  1.4 +/- 1.7  .49  
Functional capacity  n = 184  n = 160  n = 23   
Mild activities (<3 METs) 1 (0.5)  1 (0.6)  0 (0.0)   
Moderate activities (3–6 METs) 20 (10.9)  15 (9.3)  5 (21.7)   
Vigorous activities (>=6 METs) 163 (88.6)  145 (90.1)  18 (78.3)  .19  
Social support  n = 183  n = 160  n = 23   
<50 7 (3.8)  6 (3.8)  1 (4.4)   
50–75 33 (18.0)  29 (18.1)  4 (17.4)   
75–100 143 (78.1)  125 (78.1)  18 (78.3)  .98  
Satisfaction with Life  n = 178  n = 156  n = 22   
Delighted or highly satisfied 138 (77.5)  121 (77.6)  17 (77.3)   
Satisfied or lower 40 (22.5)  35 (22.4)  5 (22.7)  .97  
Mean +/- SD 6.0 +/- 0.9  5.9 +/- 0.9  6.1 +/- 1.0  .64  
Satisfaction with health  n = 178  n = 156  n = 22   
Delighted or highly satisfied 85 (47.8)  72 (46.1)  13 (59.1)   
Satisfied or lower 93 (52.3)  84 (53.9)  9 (40.9)  .26  
Mean +/- SD 5.0 +/- 1.3  5.0 +/- 1.3  5.4 +/- 1.4  .19  
Satisfaction with education by 
physician in treatment choices 
n = 178  n = 156  n = 22   
Delighted or highly satisfied 141 (79.2)  126 (80.8)  15 (68.2)   
Satisfied or lower 37 (20.8)  30 (19.2)  7 (31.8)  .17  
Mean +/- SD 6.1 +/- 0.9  6.1 +/- 0.9  5.9 +/- 1.1  .1  
*Treatment patients had either surgery or radiotherapy. 
†Observation patients had neither surgery nor radiotherapy. 
‡Unless otherwise specified, statistical significance is for chi-square test (categorical variables) or 
independent samples t test (continuous variables). 
MET, metabolic equivalent. 
Table 3. Distribution of Men by Prostate Cancer-Related and Health Characteristics  
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Expected Survival 
(years) 
Baseline CALE Score Q1 Q2 
(n = 184) (n = 170) (n = 170) 
<5 1 (0.5) 26 (15.2) 1 (0.6) 
5–10 4 (2.2) 83 (48.8) 11 (6.5) 
11–19 67 (36.4) 57 (33.5) 51 (30.0) 
>=20 112 (60.9) 4 (2.4) 107 (62.9) 
Data provided as n (%). 
CALE, co-morbidity adjusted life expectancy; Q1, How long do you expect you will live without any 
treatment for prostate cancer?; Q2, How long do you expect you will live after the treatment of your 
choice for prostate cancer? 
Table 4. Distribution of Men with Localized Prostate Cancer by Calculated Co-morbidity 
Adjusted Life Expectancy  
Tables 5 and 6 present ordinal logistic regression models for PDLO and PILT. Age, CALE, 
depression, and anxiety scores predicted both PDLO and PILT. Furthermore, PSA level 
predicted PDLO, whereas social support predicted PILT. 
 
 Unadjusted Effects 
Adjusted Effects (OR 
95% CI)  
PDLO 
=<0* PDLO = 1
† 
PDLO 
=>2‡ 
OR (95% CI) 
Age 25 62 83 1.08 (1.04–1.13) 1.01 (0.92–1.10) 
PSA level 25 62 82 0.94 (0.88–1.00) 0.93 (0.86–1.00) 
CALE 25 62 83 0.92 (0.88–0.96) 0.93 (0.84–1.02) 
Anxiety score 25 62 83 0.88 (0.81–0.96) 0.96 (0.85–1.08) 
Depression score 25 58 82 0.79 (0.67–0.93) 0.85 (0.69–1.04) 
*A (PDLO) =<0 (reference group) indicates that CALE and self-reported survival expectation without 
treatment are within the same range or CALE is less.  
†A (PDLO) = 1 suggests that CALE exceeds self-reported survival expectation without treatment by one 
response category. 
‡A (PDLO) >=2 suggests that CALE exceeds self-reported survival expectation without treatment by at 
least 2 response categories (ie., 
about 10 years). All covariates in the ordinal logistic regression model are defined as continuous 
variables. 
PDLO, perceived decrease in longevity with observation (categorized); PSA, prostate-specific antigen; 
CALE, comorbidity adjusted life expectancy; OR, odds ratio. 
Table 5. Ordinal Logistic Regression Modeling for Perceived Decrease in Longevity with 
Observation (PDLO) among Men with Localized Prostate Cancer  
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 Unadjusted Effects 
Adjusted Effects (OR 
95% CI)  PILT =<0* PILT = 1† 
PILT 
=>2‡ 
OR (95% CI) 
Age 18 87 65 1.08 (1.04–1.13) 1.09 (0.99–1.19) 
CALE 18 87 65 0.93 (0.89–0.97) 1.02 (0.93–1.12) 
Anxiety Score 18 87 65 0.89 (0.82–0.98) 0.91 (0.81–1.02) 
Depression score 18 83 64 0.93 (0.82–1.05) 1.06 (0.89–1.26) 
Social Support 18 87 65 1.01 (0.99–1.03) 1.00 (0.98–1.02) 
*PILT <=0 (reference group) indicates that CALE and self-reported survival expectation with treatment 
are within the same range or CALE is less.  
†A (PILT) = 1 suggests that CALE exceeds self-reported survival expectation with treatment by one 
response category. 
‡A (PILT) >=2 suggests that CALE exceeds self-reported survival expectation with treatment by at least 
2 response categories (ie., 
about 10 years). All covariates in the ordinal logistic regression model are defined as continuous 
variables. 
PILT, perceived increase in longevity with treatment (categorized); CALE, comorbidity adjusted life 
expectancy; OR, odds ratio.  
Table 6. Ordinal Logistic Regression Modeling for Perceived Increase in Longevity with 
Treatment (PILT) among Men with Localized Prostate Cancer  
6. Discussion 
Prostate cancer is the most common solid cancer in men. Younger patients make up a fast 
growing population that is being screen-detected and treated for low-risk LPC.25 To our 
knowledge, this is the first study to report the perceptions of newly diagnosed patients 
about how the cancer or its treatment could affect their survival. The mean age of our 
patients (61.5 years) was similar to the range of 58 to 64 years of US patients currently 
undergoing radical prostatectomy.26 The mean Gleason grade was 6.6 in our patients, 
similar to other series in which almost half of screen-detected cancers were   
“insignificant.”27 By choosing treatment, these low-risk patients had accepted the treatment 
side effects in exchange for longer anticipated survival. Our questions were designed to find 
how much longer these patients expected to live by choosing treatment. These expectations 
were evaluated after the patients had discussed their treatment options with their urologists. 
Despite their mean baseline CALE of 22.9 years, without treatment, 26 of 170 patients 
expected to live <5 years and only 4 expected to live >20 years; with treatment, only 1 
expected to live <5 years and 107 patients expected to live >20 years.   
What should these patients really be expecting? Nearly 86% of all patients diagnosed 
through PSA screening are not expected to die because of prostate cancer.28 The Connecticut 
Tumor Registry found that almost 20% of patients with Gleason grade 6 or higher who 
chose observation died as a result of LPC during a period of 20 years.29 However, all the 
Registry’s patients had been clinically diagnosed; in contrast, patients diagnosed with 
screen-detected LPC are expected to have a longer survival because of a gain in lead time. 
Patients in another commonly cited natural history study30 were also not diagnosed by PSA 
screening. A review31 found that only one randomized, high-quality trial32 could find a 
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survival benefit of treatment, but in this trial 95% of patients had cancer that was clinically 
palpable (and not detected by PSA screening), putting this cohort in an intermediate- to 
high-risk category. A study of 44,630 men found a survival benefit of treatment, 33 but only 
2.1% of the patient sample had died of prostate cancer. If adjusted for lead time provided by 
screening and also for the impairment of HRQOL that follows treatment, treatment was 
projected to enhance quality-adjusted survival by only 0.5 year. 34   
Overtreatment would be expected if patients believe that treatment will lead to a much 
longer survival. Many studies have found that nearly every patient initially wants 
eradication of the cancer. 9 In qualitative studies, some patients accepted side effects for any 
gain in survival but they were convinced that treatment would improve survival.9 
Assuming that tumors would grow exponentially, urologists at the Mayo Clinic were also of 
the opinion that only 0.3% and 14.5% of screen-detected LPCs were “clinically 
insignificant.”35 Patient anxiety caused by the new diagnosis of cancer and the consensus 
advice of specialists that LPC patients with a CALE of >10 years should choose treatment or 
be offered treatment6 will lead to high treatment rates. In 70% to 90% of patients, a 
treatment plan is usually made in a single visit to the urologist after a positive biopsy.36   
The mean Gleason grade of our patients was 6.6, and in 87% of patients the mean PSA was 
<10, both of which are low-risk categories but for which national guidelines recommend 
either observation or treatment.8 Only 12.5% of patients in our study chose observation. 
Specialists frequently recommend treatment even in low-risk patients because over 10 to 15 
years the cancer may progress.29 To manage this risk, a strategy of active surveillance with 
deferred initial treatment28 is being increasingly recommended for patients at lower risk, ie, 
with cancers of Gleason grade <7, cancer stages T1c to T2a, and PSA <10. Almost half of 
patients with screen-detected cancer possess such characteristics. 27 In conjunction with 
specialists, primary care physicians (PCPs) can follow patients who choose this strategy. 
PCPs may also offer more balanced advice because they might be more knowledgeable 
about the patient’s preferences, co-morbidities, and baseline CALE.37 Patients with LPC may 
also want to review educational materials with their PCP. The American Cancer Society 
website was recommended because its content, accuracy, balance, and readability was rated 
the highest among 44 patient education materials about LPC.38 
Overtreatment can also be reduced with decreased screening, and several studies have 
shown that fewer patients want PSA screening if they are counseled before screening.39 
Enthusiasm for routine screening is high among specialists who treat LPC. In a random 
nationwide survey, 43% of 559 radiation oncologists recommended routine PSA screening in 
average-risk patients older than 80.6 Primary care physicians who frequently order PSA 
testing without much discussion about risks and benefits of testing cited reasons of lack of 
time, competing demands, limited patient health literacy, and fear of liability.40 Prescreening 
counseling is difficult because it is unclear what and how much discussion should occur. As 
yet, we cannot say that screening or treatment can improve survival. The deleterious effects 
of treatment on urinary, bowel, and sexual dysfunction are better known; however, their 
frequencies and severities after different treatment techniques have been reported in more 
than 800 publications,41 vary greatly, and are difficult to balance. We can also share with 
patients that there is a small risk of immediate morbidity and mortality associated with 
prostate biopsy and cancer treatment; that a new anxiety results from a positive PSA test, 
whether or not it is followed by a negative biopsy; and that we cannot compare the risk of 
death caused by co-morbid diseases with that of death caused by cancer without knowing 
the grade and stage of the cancer. However, patients must also know that, even if diagnosed 
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with cancer, no randomized controlled trial has shown that treatment can or cannot improve 
survival in patients with screen-detected cancer. Interestingly, a study found that more 
African American patients wanted PSA screening after the use of a decision aid, 39 
presumably because of the appreciation of the higher risk in African American patients.  
In our patients, age, CALE, depression, and anxiety were the most important predictors of 
PDLO or PILT. Though PSA level also influenced PDLO, PILT was related to social support. 
PDLO and PILT were not related to other factors such as race; income; education; health 
literacy; physical and mental summary SF-36 scores; urinary, bowel, and sexual symptoms; 
choice of treatment or observation; fear of cancer recurrence; functional capacity; and 
satisfaction with life, health, or with education by physicians in cancer treatment options. 
Although the association of PDLO and PILT with continuous depression scores was 
statistically significant, the importance of this finding is unclear given that 96.6% patients 
had a depression score of <7, which indicates no depression. 
Our findings may be difficult to generalize because our study sample was small. However, 
the differences we found between CALE and patient expectations of survival with and 
without treatment were large. Also, the mean age26 and mean cancer grade27 of patients 
newly diagnosed with LPC in large series and in our patients were similar. Our patients 
were treated by urologists in a private practice and more than 80% of urologists in the 
United States are in private practice.42 Our method of equating CCI scores with NCCN 
recommended health quartiles to estimate CALE is new and has not been previously 
validated. We used this method because we could not find any other validated method to 
estimate long-term health-adjusted life expectancy in individual ambulatory patients. 
Finally, we lost accuracy in the estimation of PDLO and PILT by asking patients to predict 
their survival in ordinal intervals rather than in a discrete number of years. We used ordinal 
intervals because it might be easier for patients to predict their survival this way, and the 
intervals allowed an estimation of PDLO and PILT of more than or less than 10 years. We 
have also published these findings earlier. 43 
We had also studied whether our patients had adequate Knowledge, Understanding and 
Judgment (KUJ) of their treatment options by using a KUJ 18-item questionnaire that we 
have developed; we found that although the vast majority of our patients were educated, 
had good health literacy and had higher income, over half of the patients incorrectly 
answered over half of the questions on the KUJ scale. These findings have been published 
separately.44 Additionally, we had studied whether our patients had chosen treatment or 
observation in accordance with current NCCN guidelines and we had found that a majority 
had chosen over-treatment, i.e., they had chosen treatment even though for their clinical 
situation the NCCN had recommended observation as an equal alternative. These findings 
were published recently, 45 and had demonstrated that with the use of our method to 
estimate CALE it becomes feasible to use NCCN guidelines in decision-making in 
individual patients. Based on our research and NCCN guidelines, in August 2011 we have 
published a comprehensive and easy-to-understand approach in the journal American Family 
Physician (AFP)46 which can be used by newly-diagnosed patients and their physicians in 
quickly reaching an evidence-based and guideline-driven treatment choice. Decision-
making is very hard especially for low-risk patients, traditionally primary care physicians 
are not involved in this process, and over 70% to 80% patients choose a treatment or 
observation in the first visit to the urologist after a positive biopsy. Although newer 
guidelines now recommend against PSA screening,47 this recommendation carries the risk of 
increasing mortality due to prostate cancer and prostate cancer is already the second most 
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common cause of cancer death in American men. The algorithm and tools provided in our 
publication in AFP can empower primary care physicians in counseling newly-diagnosed 
patients and reduce the risk of over-treatment by convincing low-risk patients to choose 
active surveillance. With this safeguard, patients and physicians can choose screening for 
prostate cancer with less hesitation.    
7. Conclusion 
In patients with newly diagnosed LPC, in whom the mean cancer grade was <7 and in 
whom education, income, and health literacy was intermediate to high, almost 38% of our 
patients had expectations of a reduction in survival of 10 or more years if they chose 
observation, and 48.8% patients expected an improvement in survival of 10 or more years 
through choosing treatment. These expectations are highly unrealistic because no study has 
shown that the cancer or its treatment can affect survival by even 1 year, especially in 
screen-detected patients with a cancer Gleason grade of <7. 
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